RDHL
RedHill Biopharma Ltd.

7,319
Mkt Cap
$5.54M
Volume
21,073.00
52W High
$7.44
52W Low
$1.01
PE Ratio
-0.02
RDHL Fundamentals
Price
$1.20
Prev Close
$1.22
Open
$1.19
50D MA
$1.40
Beta
0.85
Avg. Volume
1.6M
EPS (Annual)
-$6.73
P/B
-0.63
Rev/Employee
$230,890.69
Loading...
Loading...
News
all
press releases
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement PR...
PR Newswire·10d ago
News Placeholder
More News
News Placeholder
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement PR Newswire...
PR Newswire·1mo ago
News Placeholder
RedHill Biopharma Receives Nasdaq Staff Determination Notification
RedHill Biopharma Receives Nasdaq Staff Determination Notification RedHill Biopharma Receives Nasdaq Staff Determination Notification PR Newswire TEL AVIV, Israel and RALEIGH, N.C., Oct. 22, 2025 On...
PR Newswire·2mo ago
News Placeholder
RedHill Biopharma Logs Best Session In Over A Year After $10M Legal Victory — Retail Sees Bullish Triggers Ahead
The stock rallied after the New York Supreme Court reaffirmed RedHill’s $10 million award in its dispute with Kukbo.
Stocktwits·2mo ago
News Placeholder
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties RedHill Licenses RHB-102 for...
PR Newswire·10mo ago
News Placeholder
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate...
PR Newswire·10mo ago
News Placeholder
RedHill's Talicia Adds 8 Million Lives With Coverage by Humana's Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published
RedHill's Talicia Adds 8 Million Lives With Coverage by Humana's Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published RedHill's Talicia Adds 8 Million Lives...
PR Newswire·11mo ago

Latest RDHL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.